Skip to main content

Freedom of information requests

FOI 4175 2024/25

Treatment of GCA

Published 28 May 2024

Treatment of GCA

Questions

  1. Does your trust or health board treat giant cell arteritis (GCA)? If not, please provide the name of the hospital or trust that you refer GCA patients to.
  2. In the past 3 months, how many patients with a primary diagnosis of GCA (ICD10 codes M31.5 or M31.6) were: Admitted as an inpatient, Treated in A&E
  3. How many patients were treated by the rheumatology department in the past 3 months with the following:
    • Tocilizumab – for any disease
    • Tocilizumab for rheumatoid arthritis (RA) only
    • Tocilizumab for giant cell arteritis (GCA) only
  4. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab?
  5. How many patients were treated in A&E in the past 3 months for giant cell arteritis (GCA) with Tocilizumab?

Response

  1. Yes
  2. FOI refusal under S14(1) (see below)
  3. FOI refusal under S14(1) (see below)
  4. FOI refusal under S14(1) (see below)
  5. FOI refusal under S14(1) (see below)